MX2022011179A - Uso medico de daridorexant. - Google Patents

Uso medico de daridorexant.

Info

Publication number
MX2022011179A
MX2022011179A MX2022011179A MX2022011179A MX2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A MX 2022011179 A MX2022011179 A MX 2022011179A
Authority
MX
Mexico
Prior art keywords
daridorexant
medical use
formula
daytime
pharmaceutically acceptable
Prior art date
Application number
MX2022011179A
Other languages
English (en)
Spanish (es)
Inventor
Guy Braunstein
Scott Pain
Dalma Seboek-Kinter
Cedric Vaillant
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2022011179A publication Critical patent/MX2022011179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022011179A 2020-04-19 2021-04-16 Uso medico de daridorexant. MX2022011179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2020060940 2020-04-19
PCT/EP2021/059943 WO2021213923A1 (en) 2020-04-19 2021-04-16 Medical use of daridorexant

Publications (1)

Publication Number Publication Date
MX2022011179A true MX2022011179A (es) 2022-10-07

Family

ID=75478068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011179A MX2022011179A (es) 2020-04-19 2021-04-16 Uso medico de daridorexant.

Country Status (14)

Country Link
US (1) US20230134935A1 (https=)
EP (1) EP4138822A1 (https=)
JP (1) JP7822954B2 (https=)
KR (1) KR20230004670A (https=)
CN (1) CN115427037A (https=)
AU (1) AU2021260018A1 (https=)
BR (1) BR112022020924A2 (https=)
CA (1) CA3175369A1 (https=)
CL (1) CL2022002855A1 (https=)
IL (1) IL297234A (https=)
MX (1) MX2022011179A (https=)
PH (1) PH12022552763A1 (https=)
TW (1) TW202200133A (https=)
WO (1) WO2021213923A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
WO2024019978A2 (en) * 2022-07-19 2024-01-25 Rutgers, The State University Of New Jersey Therapeutic combinations and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502447A (ja) * 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
MY179862A (en) 2013-12-03 2020-11-18 Idorsia Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
LT3619199T (lt) 2017-05-03 2021-09-27 Idorsia Pharmaceuticals Ltd 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba

Also Published As

Publication number Publication date
CA3175369A1 (en) 2021-10-28
TW202200133A (zh) 2022-01-01
JP2023521492A (ja) 2023-05-24
BR112022020924A2 (pt) 2023-02-14
AU2021260018A1 (en) 2022-12-22
WO2021213923A1 (en) 2021-10-28
KR20230004670A (ko) 2023-01-06
JP7822954B2 (ja) 2026-03-03
IL297234A (en) 2022-12-01
US20230134935A1 (en) 2023-05-04
EP4138822A1 (en) 2023-03-01
CL2022002855A1 (es) 2023-06-02
CN115427037A (zh) 2022-12-02
PH12022552763A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
MX2022000143A (es) Metodos novedosos.
CL2022001389A1 (es) Derivado de cicloalquilurea
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
AR100772A1 (es) Métodos para aumentar la inhibición tónica y tratar el insomnio secundario
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
AR078588A1 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
ECSP13013117A (es) Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.
WO2014141110A3 (en) Aminonitriles as kynurenine pathway inhibitors
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CL2022002855A1 (es) Uso médico de daridorexant
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
MX2017012926A (es) Inhibidores y sus usos.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2022005843A (es) Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer